JPWO2020118213A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020118213A5
JPWO2020118213A5 JP2021531818A JP2021531818A JPWO2020118213A5 JP WO2020118213 A5 JPWO2020118213 A5 JP WO2020118213A5 JP 2021531818 A JP2021531818 A JP 2021531818A JP 2021531818 A JP2021531818 A JP 2021531818A JP WO2020118213 A5 JPWO2020118213 A5 JP WO2020118213A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cdk4
resistant
inhibitor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511498A5 (https=
JP7504097B2 (ja
JP2022511498A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065005 external-priority patent/WO2020118213A1/en
Publication of JP2022511498A publication Critical patent/JP2022511498A/ja
Publication of JP2022511498A5 publication Critical patent/JP2022511498A5/ja
Publication of JPWO2020118213A5 publication Critical patent/JPWO2020118213A5/ja
Application granted granted Critical
Publication of JP7504097B2 publication Critical patent/JP7504097B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531818A 2018-12-06 2019-12-06 Cdk4/6阻害剤に耐性の癌を治療するための方法 Active JP7504097B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776323P 2018-12-06 2018-12-06
US62/776,323 2018-12-06
PCT/US2019/065005 WO2020118213A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer resistant to cdk4/6 inhibitors

Publications (4)

Publication Number Publication Date
JP2022511498A JP2022511498A (ja) 2022-01-31
JP2022511498A5 JP2022511498A5 (https=) 2022-12-19
JPWO2020118213A5 true JPWO2020118213A5 (https=) 2022-12-19
JP7504097B2 JP7504097B2 (ja) 2024-06-21

Family

ID=69063871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531818A Active JP7504097B2 (ja) 2018-12-06 2019-12-06 Cdk4/6阻害剤に耐性の癌を治療するための方法

Country Status (17)

Country Link
US (2) US20210330612A1 (https=)
EP (1) EP3890834A1 (https=)
JP (1) JP7504097B2 (https=)
KR (1) KR20210100137A (https=)
CN (2) CN113164779A (https=)
AU (1) AU2019395093B2 (https=)
BR (1) BR112021010110A2 (https=)
CA (1) CA3121930A1 (https=)
EA (1) EA202191283A1 (https=)
IL (1) IL283659A (https=)
JO (1) JOP20210137B1 (https=)
MA (1) MA54388A (https=)
MX (1) MX2021006411A (https=)
PH (1) PH12021551319A1 (https=)
SG (1) SG11202105531XA (https=)
UA (1) UA130036C2 (https=)
WO (1) WO2020118213A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102674902B1 (ko) 2016-12-01 2024-06-14 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
CN116744925A (zh) * 2020-12-14 2023-09-12 阿尔维纳斯运营股份有限公司 用四氢萘衍生物作为雌激素受体降解剂治疗乳腺癌的方法
GB202116745D0 (en) * 2021-11-19 2022-01-05 Institute Of Cancer Res Royal Cancer Hospital Prognostic and treatment response predictive method
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN116327894A (zh) * 2023-04-10 2023-06-27 上海市第一妇婴保健院 一种治疗kras突变的卵巢癌的组合药物及其应用
WO2025202871A1 (en) * 2024-03-27 2025-10-02 Pfizer Inc. Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
JP7019422B2 (ja) * 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ,インコーポレイテッド 癌を治療するための方法
KR102707399B1 (ko) * 2017-01-05 2024-09-13 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
IL279853B2 (en) * 2018-07-04 2025-01-01 Radius Pharmaceuticals Inc Polymorphic forms of RAD 1901-2HCL

Similar Documents

Publication Publication Date Title
JP2018518529A5 (https=)
RU2017140676A (ru) Способы лечения рака
JP2018514549A5 (https=)
Liu et al. Small molecule inhibitors targeting the cancers
Schlichtig et al. New oral anti-cancer drugs and medication safety
JP2022071099A5 (https=)
JPWO2023140329A5 (https=)
JP7504097B2 (ja) Cdk4/6阻害剤に耐性の癌を治療するための方法
CN108778276A (zh) 用于治疗flt3突变型增殖性疾患相关突变的克莱拉尼
WO2024211271A1 (en) Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition
JPWO2020118213A5 (https=)
Giopanou et al. RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies
CN119546292A (zh) 使用lsd1抑制剂治疗恶性周围神经鞘瘤(mpnst)的方法
Guan et al. Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis
JPWO2020118202A5 (https=)
Lai et al. Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report
RU2021116293A (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака
RU2021116084A (ru) Способы лечения рака на моделях, имеющих мутации esr1
NZ737822B2 (en) Methods of treating cancer
US20220226338A1 (en) Methods of Treating Cancer Using CHK1 Inhibitors
NZ737819B2 (en) Methods for treating cancer
WO2019174590A1 (zh) 用于治疗三阴性乳腺癌的喹啉衍生物
CN119497613A (zh) 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
Tamborero Noguera et al. Cancer bioMarkers database
US20200009085A1 (en) Methods For Treating Ovarian Cancer